Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial

Assessing the safety and pharmacokinetics of the anti-HIV monoclonal antibody CAP256V2LS alone and in combination with VRC07-523LS and PGT121 in South African women: study protocol for the first-in-human CAPRISA 012B phase I clinical trial

Introduction New HIV prevention strategies are urgently required. The discovery of broadly neutralising antibodies (bNAbs) has provided the opportunity to evaluate passive immunisation as a potential prevention strategy and facilitate vaccine development. Since 2014, several bNAbs have been isolated...

Full description

Bibliographic Details
Main Authors: Nigel Garrett, Sharana Mahomed, Edmund Capparelli, Cheryl Baxter, Tanuja Gengiah, Derseree Archary, Penny Moore, Natasha Samsunder, Dan H Barouch, John Mascola, Julie Ledgerwood, Lynn Morris, Salim Abdool Karim, Catherine Hankins, Quarraisha A Karim, Nonhlanhla Y Zuma, Carolyn Williamson, Patricia E Fast, Bruno Pozzetto, Kevin Carlton, Nicole Doria-Rose
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/10/11/e042247.full

Internet

https://bmjopen.bmj.com/content/10/11/e042247.full

Similar Items